Cargando…
Autosomal dominant cerebellar ataxias: Imaging biomarkers with high effect sizes
OBJECTIVE: As gene-based therapies may soon arise for patients with spinocerebellar ataxia (SCA), there is a critical need to identify biomarkers of disease progression with effect sizes greater than clinical scores, enabling trials with smaller sample sizes. METHODS: We enrolled a unique cohort of...
Autores principales: | Adanyeguh, Isaac M., Perlbarg, Vincent, Henry, Pierre-Gilles, Rinaldi, Daisy, Petit, Elodie, Valabregue, Romain, Brice, Alexis, Durr, Alexandra, Mochel, Fanny |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6005808/ https://www.ncbi.nlm.nih.gov/pubmed/29922574 http://dx.doi.org/10.1016/j.nicl.2018.06.011 |
Ejemplares similares
-
Survival and severity in dominant cerebellar ataxias
por: Monin, Marie-Lorraine, et al.
Publicado: (2015) -
Multiparametric in vivo analyses of the brain and spine identify structural and metabolic biomarkers in men with adrenomyeloneuropathy
por: Adanyeguh, Isaac M., et al.
Publicado: (2021) -
IGF-1 in autosomal dominant cerebellar ataxia - open-label trial
por: Sanz-Gallego, Irene, et al.
Publicado: (2014) -
A heterozygous GRID2 mutation in autosomal dominant cerebellar ataxia
por: Koh, Kishin, et al.
Publicado: (2022) -
Autosomal recessive cerebellar ataxias
por: Palau, Francesc, et al.
Publicado: (2006)